Pre-Made Efbemalenograstim Alfa Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 for drug discovery and mechanism of action (MOA) research

Pre-Made Efbemalenograstim Alfa Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efbemalenograstim Alfa contains a recombinant fusion protein containing G-CSF at the amino terminal and human IgG2-Fc fragment at the carboxyl terminal. It is used to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-812-1mg	1mg	3090
GMP-Bios-INN-812-10mg	10mg	Inquiry
GMP-Bios-INN-812-100mg	100mg	Inquiry
GMP-Bios-INN-812-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Efbemalenograstim Alfa Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7
INN Name	Efbemalenograstim Alfa
Target	CSF3R/G-CSF-R
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [CSF3 (colony stimulating factor 3, GCSF, granulocyte colony- stimulating factor, G-CSF)]2 - IGHG2
VD LC	Fusion - [CSF3 (colony stimulating factor 3, GCSF, granulocyte colony- stimulating factor, G-CSF)]2 - IGHG2
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Generon Corporation (Shanghai) Ltd. (Shanghai China)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0